The Dark Side of the Bright Side | GenomeWeb

Many pharmaceutical companies have been cutting their R&D budgets, and now, many biotechs are following suit, says Pharmalot's Ed Silverman. Even as biotech revenues are rising, companies are keeping hold of their cash and spending less on innovative research. "Overall, biotechs spent $54 million on R&D in 2010, which is down 7 percent from the previous year. This followed a 9 percent decline in spending in 2009," Silverman says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.